Alligator Bioscience announces publication of clinical phase I data for ADC-1013 in the International Journal of Cancer.
NORDIC BUSINESS REPORT-January 30, 2019-Alligator Bioscience announces publication of clinical phase I data for ADC-1013 in the International Journal of Cancer
(C)2019 M2 COMMUNICATIONS http://www.m2.com
Alligator Bioscience AB (STO:ATORX), a clinical-stage biotechnology company developing tumour-directed immuno-oncology antibody drug, announced on Tuesday the publication of the results from a clinical phase I first-in-human study of the CD40 agonistic antibody ADC-1013 (JNJ-64457107).
These results were published in the International Journal of Cancer, in an article titled, 'First-in-human study with intratumoural administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies.'
Reportedly, top line data from this study was presented at the Society for Immunotherapy of Cancer (SITC) in November 2017.
According to the company, these results show that the agonistic anti-CD40 antibody ADC-1013 is safe and tolerated at clinically relevant dose levels. Also, the pharmacodynamic effects and the preclinical data support the further clinical development of ADC -1013 against cancer and demonstrate the potential of ADC-1013 as a combination therapy with PD-1 targeted therapies.
Also, a second phase I study assessing the safety and tolerability of intravenously administered ADC-1013 is ongoing with Janssen Biotech Inc as a sponsor and is not part of the current publication.
In August 2015, Alligator Bioscience had licensed global development rights for ADC-1013 (JNJ -64457107) to Janssen Biotech Inc, which is currently performing a phase I dose-escalation clinical study (ClinicalTrials: NCT02829099) with intravenous administration of ADC-1013.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Publication:||Nordic Business Report|
|Date:||Jan 30, 2019|
|Previous Article:||Lagercrantz's profit up by 26% in Q3 2018/19.|
|Next Article:||Suominen reports on board proposals by nomination board to 2019 AGM.|